louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00632892: The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity
Official title: The Correlation Between Oxidative Stress and Indinated Contrast-Media Nephrotoxicity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Diseases
Keywords: oxidative stress markers in urine
urine norepinephrine
renal tubular enzyme markers
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2008-03-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Adult patients (\> 18 years old)
2. Undergoing IVP with an appropriate medical indication
3. Signing informed consent

Brief summary: Clinically, iodinated contrast-medium (CM) is widely used in angiography and computerized tomography. CM-induced nephropathy (CMIN) is one major complication after application of CM. Therefore, how to prevent CMIN is always one of the hot topics concerned by nephrologists, cardiologists, and radiologists.

The present study is aimed to determine the norepinephrine concentration, oxidative markers, and tubular damage markers in the urine samples of patients undergoing intravenous pyelography (IVP).

The working hypothesis is high-osmolarity contrast media (HOCM) causes more oxidative stress and greater tubular damage than iso-osmolarity contrast media (IOCM).


Eligibility criteria: Inclusion Criteria:

1. Adult patients (\> 18 years old)
2. Undergoing IVP with an appropriate medical indication
3. Signing informed consent

Exclusion Criteria:

1. Without signing informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pan Chiao, Taipei
country: Taiwan
facility: Far Eastern Memorial Hospital
Study officials:
References:
Clinical trial NCT03973892: Remote Brain Microhaemorrhages May Predict Haematoma in Glioma Patients Treated With Radiation Therapy
Official title: Remote Brain Microhaemorrhages May Predict Haematoma in Glioma Patients Treated With Radiation Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glioma
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2019-06-04
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with glioma and folllow up with magnetic resonance imaging

Brief summary: the study aim to evaluate the prevalence of cerebral remote microhaemorrhages (RMH) and remote haematomas (RH) using magnetic resonance susceptibility-weighted imaging (SWI) among patients treated for gliomas during follow-up.


Eligibility criteria: Inclusion Criteria:

* glioma

Exclusion Criteria:

-

Primary outcomes:
measure: number of microhaemorrhages (RMH) on magnetic resonance imaging
timeFrame: one year
measure: number of remote haematomas (RH) on magnetic resonance imaging
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01945892: Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome
Official title: Ozurdex as an Treatment Option for Macula Edema Due to Irvine Gass Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Macular Edema
Visual Acuity
Keywords: macular edema, irvine gass syndrome, ozurdex
Lead sponsor: Ludwig-Maximilians - University of Munich
Sponsor class: OTHER
Collaborators: name: Allergan
First posted: 2013-09-19
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients older than 18 years.

Brief summary: To analyze macula edema formation after cataract surgery called Irvine-Gass-Syndrome.

Detailed description: 20 to 25 patients suffering from Irvine Gass Syndrom should be monitored for at least six months, controlled monthly. In all cases best corrected visual acuity, Spectralis-OCT (volume thickness scan), fundus photography (Optomap), intraocular pressure, slitlamp assessment and indirect ophthalmoscopy should be performed on every visit. Fluorescein angiography should be performed at baseline and after 3 and 6 months.

Inclusion criteria:

Patients older than 18 years who develop macula edema secondary to cataract surgery.

- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an "on label" indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of "Uveitis posterior".

Exclusion criteria:

Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of systemic, periocular, or intraocular corticosteroids within 30 days.

Outcome:

* BCVA
* Patients suffering from diabetes mellitus should be evaluated also separately.
* Change in central retinal thickness using optical coherence tomography (OCT)
* Secondary parameters (elevated IOP, retinal detachments, vitreous hemorrhage, endophthalmitis rates)

Eligibility criteria: Inclusion Criteria:

Patients older than 18 years who develop macula edema secondary to cataract surgery

Exclusion Criteria:

Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of systemic, periocular, or intraocular corticosteroids within 30 days.

Primary outcomes:
measure: Visual acuity
timeFrame: 12 months
Secondary outcomes:
measure: Retinal Thickness
timeFrame: 12 months
measure: Intraocular pressure
timeFrame: 12 months
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Dept. of Ophthalmology, LMU Munich
Study officials:
affiliation: LMU Munich
name: Wolfgang J Mayer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: LMU Munich
name: Christos Haritoglou, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04843592: SOKARY Mobile Application With Type II Diabetes
Official title: Effectiveness of Using SOKARY Mobile Application on Compliance of Patient With Type II Diabetes: A Quasi- Experimental Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type II Diabetes
Keywords: Mobile phone application
DM type II
EGYPT
Compliance
Lead sponsor: Beni-Suef University
Sponsor class: OTHER
First posted: 2021-04-13
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient with type II DM

Brief summary: Android mobile application named (SOKARY)

Detailed description: Android mobile application named (SOKARY) which means diabetes was selected as an example of mobile health application as it has the advantage of Arabic interface, free use it allows users to record his/their blood glucose level, nutrition and physical activity, then provide the user with statistics for those readings. The application also sends notifications to the users such as medication reminders and healthy lifestyle advice.

Eligibility criteria: Inclusion Criteria:

* Be familiar with the use of mobile health applications.
* Own a smartphone with an android operating system.
* Able to use the internet either through Wi-Fi network and\\or mobile data.

Exclusion Criteria:

-

Primary outcomes:
measure: the patient's compliance after using SOKARY mobile app
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT00652392: Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
Official title: A 12 Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active-controlled Study of Symbicort pMDI Administered Once Daily in Adults and Adolescents With Asthma - STEM
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: asthma
adolescents
adults
Symbicort
budesonide/formoterol
budesonide
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-03
Enrollment: 750
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare a dose of Symbicort taken once daily with other dosage regimens of Symbicort , budesonide and placebo for the treatment of asthma in adolescents and adults


Eligibility criteria: Inclusion Criteria:

* Diagnosis of asthma and baseline lung function tests as determined by the protocol
* Required and received treatment with inhaled corticosteroids within the timeframe and doses specified in the protocol

Exclusion Criteria:

* Severe asthma
* Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in protocol or requires treatment with beta-blockers

Primary outcomes:
measure: Change in evening PEF
timeFrame: Daily throughout the 12 week treatment period
Secondary outcomes:
measure: Lung function, asthma symptoms, use of rescue medication and parent/caregiver/physician reported outcomes
timeFrame: Daily throughout the 12 week treatment period
measure: Health-related quality of life
timeFrame: 4 assessments within 12 week treatment period
measure: Routine safety assessments
timeFrame: 4 assessments within 12 week treatment period
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: Catherine Bonuccelli
role: STUDY_DIRECTOR
References:
citation: Berger WE, Bleecker ER, O'Dowd L, Miller CJ, Mezzanotte W. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma. Allergy Asthma Proc. 2010 Jan-Feb;31(1):49-59. doi: 10.2500/aap.2010.31.3309.
Clinical trial NCT03739892: Biomarkers to Predict Gain From Therapy in Motor Stroke
Official title: Biomarkers to Predict Gain From Therapy in Motor Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Motor Activity
Biomarker
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2018-11-14
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: physiopathological study
Primary purpose: OTHER

Brief summary: The aim is to determine predictors of treatment response, i.e gain from rehabilitation training, in post stroke upper limb deficits. The investigators will like to answer the following question: "What is this patient's potential for recovery, given his profile?" The investigators propose to conduct a longitudinal physiopathological study on the stroke patients with motor deficits who entered the rehab center of Pitié Salpêtrière hospital. The investigators will benefit from the organization, which is already in place (clinical asssessments and training) to add MRI, TMS and EEG recordings, as well as genotype analysis before the training offered in the rehabilitation unit. The investigators will repeat these assessments after the training (immeadiately and 6 weeks after).

Detailed description: The protocol is based on 10 visits. The three main one are V1, V9 and V10. V1, V9 and V10 are the assessments visits with clinical scores, MRI TMS and EEG recordings. These are made before the training (V1), immediately after the 6 weeks of training (V9) and 6 weeks after (V10) V5 is a visit where the investigators will clinically assess the patients at three weeks of the training.

The other visits (V2, V3, V4, V6, V7, V8) consist in recording an EEG while patients are under training each week during six weeks.

Eligibility criteria: Inclusion Criteria:

(i) First-ever stroke patients (ii) Upper limb motor impairment (Fugl Meyer scale) (iii) post stroke delay between 7 and 42 days (iv) affiliated to french health care (v) Suitable for task based oriented training in the rehab center

Exclusion Criteria:

(i) age \< 18 or \> 85 years (ii) Hemianopia (iii) contra-indications to MRI or TMS assessments (iv) life threatening conditions (v) patients under legal protection (vi) pregnancy

Primary outcomes:
measure: Changes in a composite motor score post-pre training is the gain from therapy Candidates biomarkers: MRI, EEG, TMS, genotype
timeFrame: 6 weeks between pre and post assessment
Secondary outcomes:
measure: Changes in a composite motor score post-pre training is the gain from therapy
timeFrame: 12 weeks between pre and post assessment
Other outcomes:
Locations:
city: Paris
country: France
facility: ICM
Study officials:
References:
Clinical trial NCT05776992: Effect of Various Virtual Reality Exercise Individuals With Low Back Pain
Official title: Effect of Different Virtual Reality Exercise in Nonspecific Individuals With Low Back Pain
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Low Back Pain
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2023-03-20
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prior to and following the eight-week application, evaluation was conducted
Primary purpose: OTHER

Brief summary: Posture is defined as the best position formed by the segments that make up the body in a harmonious arrangement with each other. Muscle strength, which is one of the primary factors in providing a static or dynamic posture, is achieved thanks to the antigravity muscles that keep the body upright against gravity. Proper posture is ensured by a good body balance.

Detailed description: Advances in technology can influence healthcare providers to create alternative and new treatment options. SG/LV applications have also gained momentum in the field of rehabilitation. Studies have shown that 12-week programs, especially in diseases affecting the balance and vestibular system, can achieve more effective results than standard physiotherapy programs in both upper and lower extremity functions, balance, walking parameters, fall risk and cognitive parameters. The use of popular video game-based exercises, such as XBOX, or "exergaming," has evolved to become therapeutic tools for rehabilitation. Accessible as technology evolves into more and more, equipment like biodex could be an alternative way to assess and train balance

Eligibility criteria: Inclusion Criteria:

* 18-60 with nonspecific chronic low back pain

Exclusion criteria from the study:

* Cognitive impairment
* Disc herniation
* Neurological deficit
* Respiratory problems

Primary outcomes:
measure: The Visual Analogue Scale (VAS)
timeFrame: 6 weeks
measure: Y Balance Test
timeFrame: 6 weeks
measure: Oswestry Low Back Pain Disability Questionnaire
timeFrame: 6 weeks
measure: Algometer
timeFrame: 6 weeks
measure: Body Awareness Questionnaire
timeFrame: 6 weeks
measure: Flamingo Static Balance Evaluation Test:
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: HAZAL genç
state: None Selected
Study officials:
References:
citation: Dayanir IO, Birinci T, Kaya Mutlu E, Akcetin MA, Akdemir AO. Comparison of Three Manual Therapy Techniques as Trigger Point Therapy for Chronic Nonspecific Low Back Pain: A Randomized Controlled Pilot Trial. J Altern Complement Med. 2020 Apr;26(4):291-299. doi: 10.1089/acm.2019.0435. Epub 2020 Feb 5.
Clinical trial NCT01120392: Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease
Official title: Virtual Reality in Motor Performance and Quality of Life in Patients With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Parkinson Disease
Keywords: Parkinson's disease
Physical therapy
Virtual Reality
Quality of life
Motor performance
Lead sponsor: Federal University of Bahia
Sponsor class: OTHER
First posted: 2010-05-11
Enrollment: 40
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treatment with Nintendo wii is higher to physical therapy conventional in the quality of life and motor performance in patients with Parkinson's disease.

Detailed description: The aim of this study is to assess if the treatment of rehabilitation with Nintendo wii is higher to the conventional in the quality of life and motor performance in patients with Parkinson's disease.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Parkinson's disease
* Both the sex with age between 50 and 80 years
* To be in it I serve as apprentice of 1 the 3,0 in the scale of Hoehn Yahr

Exclusion Criteria:

* Cognitive impairment
* Poorly controlled arterial hypertension
* Poorly controlled Cardiopathy

Primary outcomes:
measure: Quality of life
timeFrame: 4 weeks (Baseline and after four weeks)
measure: Motor performance
timeFrame: 4 weeks (Baseline and after four weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Salvador
country: Brazil
facility: Ambulatorio Magalhães Neto
state: Bahia
Study officials:
affiliation: UFBA- DINEP
name: Ailton Melo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03536689: Comparison of Amniotic Fluid Index Between Before and After Maternal Position Change in Upright and Left Lateral Decubitus Position
Official title: Randomized Controlled Trial of Amniotic Fluid Index Compared Between After Upright and Left Lateral Decubitus Maternal Position Change
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pregnancy Related
Keywords: Amniotic fluid index
Lead sponsor: Department of Medical Services Ministry of Public Health of Thailand
Sponsor class: OTHER_GOV
First posted: 2018-05-25
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 34
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: Factorial 2-by-2 open labeled randomised controlled trial
Primary purpose: DIAGNOSTIC

Brief summary: Comparison of amniotic fluid index between before and after maternal position change in Upright and left lateral decubitus maternal position

Detailed description: Amniotic fluid has many important roles in fetal development such as the development of the digestive tract and respiratory system. The quantity of amniotic fluid can be measured by ultrasonography, measuring the deepest pocket in 4 quadrants of uterus then summarize as one value known as "amniotic fluid index"(AFI). The AFI has the normal range between 5-25 cm. The low AFI (\< 5 cm) is associated with abnormal fetal heart rate, and the abnormal AFI does affect to the treatment during the antepartum and intrapartum phase. However , there is the study shown that when compared to the single deepest pocket (SDP) , AFI could detect the oligohydramnios more which might led to the unnecessary labor induction or operative delivery without the significant change of perinatal outcome. To increase the accuracy of AFI, we theorize that maternal position change might affect the amniotic fluid position which would increase the visual of the amniotic fluid as well.

Eligibility criteria: Inclusion Criteria:

* Pregnant women age 20-34 years whose gestational age was confirmed by ultrasonography before 24 weeks of gestation

Exclusion Criteria:

* Pregnant women with multifetal pregnancy
* Pregnant women who have underlying disease
* Pregnant women who have the history of premature rupture of amniotic membrane
* Pregnant women who have amniotic fluid index below 5 cm (oligohydramnios)
* Pregnant women who have amniotic fluid index more than 25 cm (polyhydramnios)
* Pregnant women whose her baby has the fetal anomaly

Primary outcomes:
measure: Amniotic fluid index change after maternal position change
timeFrame: 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Rajavithi Hospital
Study officials:
affiliation: Department of Medical Services Ministry of Public Health of Thailand
name: Tirawat Chotkittikul, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02253589: Motivational Interviewing (MI) to Reduce Khat Use
Official title: Evaluation of Motivational Interviewing (MI) to Reduce Khat Use Among Somali Refugees in Kenya
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Khat Use Disorder
Lead sponsor: University of Konstanz
Sponsor class: OTHER
Collaborators: name: Africa Mental Health Foundation
First posted: 2014-10-01
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Healthy khat user with the intention to reduce or stop khat use will be randomly assigned to a one-session brief intervention or waiting list. Reductions in khat use will be measured from pre- to post-assessment which will be one month apart. After one month, the waiting list will receive the same intervention.

Detailed description: The leaves of the khat tree are traditionally chewed in some African and Arab countries. They contain the mild central stimulant cathinone. In recent years, the production, trade and use has dramatically increased and excessive patterns of use as well as a specific dependence syndrome have been described. So far, no experiences exist in psychological treatment of khat addiction.

In this study, we use a brief motivational intervention based on the WHO's ASSIST-linked Brief Intervention and Motivational Interviewing to support users who have the intention to reduce or stop their khat use. Khat users will be recruited in the community. Trained local staff will assess participant's khat and other substance use at study entry and one month later. Users will be assigned randomly to intervention or waiting list control groups. The intervention group will receive a single 20-minute brief intervention. The waiting list will receive the same intervention after the second assessment. After two months, a final assessment will be made in both groups.

Eligibility criteria: Inclusion Criteria:

Healthy individuals

Exclusion Criteria:

Severe psychiatric disorders

Primary outcomes:
measure: Time-Line-Follow-Back: Self-reported days with khat use and amount of khat use
timeFrame: one month
Secondary outcomes:
measure: Time-Line-Follow-Back: other substance use
timeFrame: One month
Other outcomes:
Locations:
city: Nairobi
country: Kenya
facility: Tawakal Clinic
Study officials:
References: